Implementing Higher Molar Dose in Your Clinical Practice

In this podcast, John Kitchens, MD, is joined by Peter Kaiser, MD. They discuss higher molar dose and share pearls and their clinical best practices.

What are the challenges when treating patients with higher molar doses? How can clinicians help patients transition to a higher dose? Listen and find out today.

Don't miss the full podcast – or the key takeaways below.

Increasing aflibercept dose for longer drug duration in eyes.

• A deep dive into how increasing aflibercept dose improves drug durability in the eye
• Modeling suggests slower ocular clearance with higher dose of aflibercept

Drug half-life and dosing for anti-VEGF treatments in ophthalmology.

• How the half-life of aflibercept is determined in the eye using PK sampling and modeling
• Highlights of studies include dose regimen modifications and durability of drug in second year

Accelerating aflibercept dosing intervals for wet AMD patients.

• Designing clinical studies translating the "treat and extend" approach to the real world
• Potential benefits of longer-acting eye medication, including increased efficiency and reduced burden on healthcare providers
• Potential biomarkers that indicate a need for frequent VEGF injections in wet AMD patients
• Emphasising the importance of early treatment with the strongest medication for type three lesions to prevent permanent vision loss